Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2023. For the year, the company expects net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and basic loss per share of JPY 177.35.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
650 JPY | +13.24% | +20.59% | -13.56% |
1st Jan change | Capi. | |
---|---|---|
-13.56% | 24.29M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- 4884 Stock
- News Kringle Pharma, Inc.
- Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023